Key facts
- This page summarizes Paul McBarron's Form 4 filing for Cyclacel Pharmaceuticals, Inc. (CYCC).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 26 Dec 2023, 16:05.
Paul McBarron - 21 Dec 2023 Form 4 Insider Report for Cyclacel Pharmaceuticals, Inc. (CYCC)
- Reporting relationship
- E. VP, Fin, CFO, COO and Secretary, Director
- Issuer ticker
- CYCC
- Reported as of
- 21 Dec 2023
- Net transaction value
- +$6,252
- SEC form
- 4
- Accepted by SEC
- 26 Dec 2023, 16:05:25 UTC
- Prior SEC filing
- 03 Jul 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Paul McBarron
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Paul McBarron filed Form 4 for Cyclacel Pharmaceuticals, Inc. (CYCC) on 26 Dec 2023.
Change
- Previous filing in this sequence was filed on 03 Jul 2023.
- Current net transaction value: +$6,252.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
CYCC
transaction
Common Stock
Purchase
- Transaction value
- $6,252
- Shares
- +1,886
- Change %
- +6%
- Price
- $3.32
- Shares after
- 33,378
- Date
- 21 Dec 2023
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
CYCC
transaction
Derivative
Warrants (right to buy)
Purchase
- Transaction value
- $0
- Shares
- +1,886
- Change %
- Price
- $0.000000
- Shares after
- 1,886
- Date
- 21 Dec 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 1,886
- Exercise price
- $3.19
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The Reporting Person purchased unregistered shares of the Issuer's common stock in a private placement, pursuant to a Securities Purchase Agreement between the Reporting Person and the Issuer.
Footnote F2
Each share of common stock was purchased with an accompanying warrant at an aggregate purchase price of $3.315 per share and accompanying warrant.
SEC remarks
E. VP, Fin, CFO, COO and Secretary